Parnax Lab Ltd Stock Price Today (NSE: PARNAXLAB)
Fundamental Score
Parnax Lab Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Parnax Lab Ltd share price today is ₹128.55, down 2.85% on NSE/BSE as of 30 March 2026. Parnax Lab Ltd (PARNAXLAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹141.27 (Cr). The 52-week high for PARNAXLAB share price is ₹146.80 and the 52-week low is ₹85.60. At a P/E ratio of 12.81x, PARNAXLAB is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 15.14% and a debt-to-equity ratio of 0.77.
Parnax Lab Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Parnax Lab Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Parnax Lab Share Price: A Financial Analysis of Industry Dominance
In the dynamic pharmaceutical industry, a critical success factor is agility in responding to evolving regulatory landscapes and patent expirations. Companies that effectively navigate these challenges are positioned for sustained growth. This analysis delves into the current financial standing of Parnax Lab Ltd, focusing on its valuation and profitability metrics, particularly as reflected in the Parnax Lab share price of ₹119.0. We will examine key indicators and compare them against sector peers to assess the company’s potential for industry dominance.
Currently, Parnax Lab trades at a Price-to-Earnings (PE) ratio of 12.81. To put this into perspective, a closer look at its sector peers is necessary.
Mankind Pharma Ltd, for instance, often commands a premium PE multiple, potentially reflecting investor confidence in its management quality and brand recognition. It would be insightful to conduct a deep dive comparing Parnax Lab's operational efficiency, sales conversion, and management expertise to understand the gap, if any, with leaders like Mankind Pharma Ltd. Similarly, evaluating Parnax's strategies against competitors like Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd regarding niche market penetration and product portfolio diversification can provide valuable context.A crucial element impacting Parnax Lab's competitive advantage, or "moat," is its Return on Capital Employed (ROCE) of 13.97%. This figure indicates the efficiency with which the company generates profits from its invested capital. A consistently high ROCE, sustained over time, suggests a strong moat, allowing Parnax Lab to reinvest profits at attractive rates, fostering further growth and making it difficult for competitors to erode its market position. However, it's essential to examine the trend of the ROCE over several years to ascertain its sustainability and the factors driving it. For instance, one-time gains could skew the ROCE, while consistent organic growth provides a more reliable indicator of a strong moat.
This analysis of the Parnax Lab share price is part of a comprehensive 80-parameter fundamental audit meticulously verified by Sweta Mishra. It is observational in nature and does not constitute investment advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Parnax Lab Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of PARNAXLAB across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Return on Equity (15.14%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Attractive Valuation (P/E: 12.81 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Revenue Growth (29.45%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (14.52% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (37.86% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (43.21% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Balanced Promoter Holding (72.29%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Risk Factors
1 factors identified
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Parnax Lab Ltd Financial Statements
Comprehensive financial data for Parnax Lab Ltd including income statement, balance sheet and cash flow
About PARNAXLAB (Parnax Lab Ltd)
Parnax Lab Ltd is a pioneering force within the pharmaceutical industry, dedicated to advancing healthcare solutions through innovative research, development, and manufacturing. Wi...th a steadfast commitment to quality and efficacy, Parnax Lab specializes in creating a diverse portfolio of pharmaceutical products designed to address a wide spectrum of medical needs. The company’s state-of-the-art facilities adhere to stringent global regulatory standards, ensuring the production of safe and reliable medications that meet the highest benchmarks of excellence. Parnax Lab's driving mission is to enhance patient well-being by delivering accessible and affordable pharmaceutical products that improve lives around the world. Parnax Lab's product range encompasses a comprehensive array of therapeutic categories, catering to diverse patient populations and healthcare requirements. From advanced treatments for chronic conditions to essential medications for everyday ailments, Parnax Lab is committed to providing comprehensive healthcare solutions. Specifically, Parnax Lab excels in developing and manufacturing specialized treatments including; liquid suspensions, soothing topical ointments, skin rejuvenating creams, and convenient tablet and capsule forms. This diverse manufacturing capability allows for the development of treatments for a broad range of medical conditions including digestive issues, and pediatric formulations. Parnax Lab continues to push the boundaries of pharmaceutical innovation to create products that are truly life-changing. Driven by a passion for scientific discovery and a relentless pursuit of excellence, Parnax Lab fosters a culture of innovation and collaboration among its team of experienced scientists, researchers, and healthcare professionals. Parnax Lab maintains a strong emphasis on ethical practices and environmental responsibility throughout its operations, striving to create a sustainable and socially responsible business. With a global outlook and a local focus, Parnax Lab is dedicated to building lasting partnerships with healthcare providers, distributors, and patients to ensure that its products reach those who need them most, making a tangible difference in healthcare outcomes.
Company Details
Key Leadership
Latest News
PARNAXLAB Share Price: Frequently Asked Questions
What is the current share price of Parnax Lab Ltd (PARNAXLAB)?
As of 30 Mar 2026, 12:02 pm IST, Parnax Lab Ltd share price is ₹128.55. The PARNAXLAB stock has a market capitalisation of ₹141.27 (Cr) on NSE/BSE.
Is PARNAXLAB share price Overvalued or Undervalued?
PARNAXLAB share price is currently trading at a P/E ratio of 12.81x, compared to the industry average of 31.77x. Based on this relative valuation, the Parnax Lab Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of PARNAXLAB share price?
The 52-week high of PARNAXLAB share price is ₹146.80 and the 52-week low is ₹85.60. These values are updated daily from NSE/BSE price data.
What factors affect the Parnax Lab Ltd share price?
Key factors influencing PARNAXLAB share price include quarterly earnings growth (Sales Growth: 29.45%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Parnax Lab Ltd a good stock for long-term investment?
Parnax Lab Ltd shows a 5-year Profit Growth of 43.21% and an ROE of 15.14%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.77 before investing in PARNAXLAB shares.
How does Parnax Lab Ltd compare with its industry peers?
Parnax Lab Ltd competes with major peers in the Pharmaceuticals. Investors should compare PARNAXLAB share price P/E of 12.81x and ROE of 15.14% against the industry averages to determine competitive standing.
What is the P/E ratio of PARNAXLAB and what does it mean?
PARNAXLAB share price has a P/E ratio of 12.81x compared to the industry average of 31.77x. Investors pay ₹13 for every ₹1 of annual earnings.
How is PARNAXLAB performing according to Bull Run's analysis?
PARNAXLAB has a Bull Run fundamental score of 55/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does PARNAXLAB belong to?
PARNAXLAB operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Parnax Lab Ltd share price.
What is Return on Equity (ROE) and why is it important for PARNAXLAB?
PARNAXLAB has an ROE of 15.14%, which indicates excellent management efficiency. ROE measures how efficiently Parnax Lab Ltd generates profits from shareholders capital.
How is PARNAXLAB debt-to-equity ratio and what does it indicate?
PARNAXLAB has a debt-to-equity ratio of 0.77, which indicates moderate leverage that should be monitored.
What is PARNAXLAB dividend yield and is it a good dividend stock?
PARNAXLAB offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Parnax Lab Ltd shares.
How has PARNAXLAB share price grown over the past 5 years?
PARNAXLAB has achieved 5-year growth rates of: Sales Growth 14.52%, Profit Growth 43.21%, and EPS Growth 37.86%.
What is the promoter holding in PARNAXLAB and why does it matter?
Promoters hold 72.29% of PARNAXLAB shares, with 9.41% pledged. High promoter holding often indicates strong management confidence in Parnax Lab Ltd.
What is PARNAXLAB market capitalisation category?
PARNAXLAB has a market capitalisation of ₹141 crores, placing it in the Small-cap category.
How volatile is PARNAXLAB stock?
PARNAXLAB has a beta of N/A. A beta > 1 suggests the Parnax Lab Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is PARNAXLAB operating profit margin trend?
PARNAXLAB has a 5-year average Operating Profit Margin (OPM) of 13.36%, indicating the company's operational efficiency.
How is PARNAXLAB quarterly performance?
Recent quarterly performance shows Parnax Lab Ltd YoY Sales Growth of 29.45% and YoY Profit Growth of 6.45%.
What is the institutional holding pattern in PARNAXLAB?
PARNAXLAB has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Parnax Lab Ltd stock.